A Phase 1/2 Study to Evaluate Safety, Pharmacokinetics and Efficacy of Isatuximab in Combination With Cemiplimab in Patients With Relapsed/Refractory Multiple Myeloma

Trial Profile

A Phase 1/2 Study to Evaluate Safety, Pharmacokinetics and Efficacy of Isatuximab in Combination With Cemiplimab in Patients With Relapsed/Refractory Multiple Myeloma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Aug 2018

At a glance

  • Drugs Cemiplimab (Primary) ; Isatuximab (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 20 Mar 2018 Status changed from not yet recruiting to recruiting.
    • 29 Jan 2018 Study design changed to parallel and randomized. Treatment arms has been changed to 1 to 3. Also there is change in planned patient number from 70 to 105.
    • 29 Jan 2018 Planned number of patients changed from 70 to 105.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top